BeiGene, Ltd. (BGNE)

162.25 +0.24 (+0.15%) At close: 04:00PM EDT

BeiGene, Ltd.

94 Solaris Avenue
Camana Bay KY1-1108
Cayman Islands
345-949-4123
https://www.beigene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10,600

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John V. Oyler	Co-Founder, Executive Chairman & CEO	2.43M	N/A	1968
Dr. Xiaobin Wu Ph.D.	President & COO	1.7M	N/A	1962
Mr. Yang Ji	Chief Compliance Officer	N/A	N/A	N/A
Dr. Yan Qi	Senior VP & Head of Public Affairs - Greater China	N/A	N/A	N/A
Mr. Jason W. Radford	Senior Vice President of Strategy & Corporate Development	N/A	N/A	1982
Dr. Mark Lanasa	Senior VP & Chief Medical Officer for Solid Tumors	N/A	N/A	N/A
Mr. Graham Hardiman	Global Head of Human Resources	N/A	N/A	N/A
Mr. Luo Lusong Ph.D.	Head of External Innovation & Senior VP	N/A	N/A	N/A
Dr. Steven Young	Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Wang Zhiwei Ph.D.	Research Head of Chemistry & Senior VP	N/A	N/A	1971

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Corporate governance

BeiGene, Ltd.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.